![](\"https:\/\/mms.businesswire.com\/media\/20260625379130\/en\/2839144\/22\/PSM_logo.jpg\"){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260625379130\/en\/2839144\/21\/PSM_logo.jpg\"){kind=logo}
<\/a>\nToday, emboldened by a lack of regulatory enforcement, telehealth companies and compounding entities are producing and marketing large volumes of unapproved compounded medications. These deceptively advertised compounded drugs carry significant risks for patients because they exist outside of the FDA\u2019s rigorous review and approval system and they raise concerns about transparency and informed decision-making. PSM\u2019s new report is a call to action for stricter enforcement of compounding violations, foreign imports and deceptive marketing and the development and implementation of new laws and policies that will help keep patients safe.<\/p>
\n\"The availability of unauthorized GLP-1 knockoffs risks the safety of millions of Americans who do not recognize the dangers of these drugs,\u201d PSM Executive Director Shabbir Imber Safdar said. \u201cFrom dosing errors to quality and sterility concerns, too many Americans have already suffered at the hands of an industry that continues to pursue commercial interests at the expense of unsuspecting patients. We\u2019re pleased to share this action plan as a guide for policymakers to uphold America's safety standards, empower the FDA to hold bad actors to account, and protect patients from substandard and dangerous medications.\u201d<\/p>
\nPSM invites partners, lawmakers, and agency leaders to join them in building on initial steps taken this year and putting the recommendations into action.<\/p>
\nAbout the Partnership for Safe Medicines<\/b><\/p>
\nThe Partnership for Safe Medicines (PSM) is a public health group comprised of non-profit organizations that handle medicine from the factory floor to the patient and are committed to the safety of prescription drugs. To learn more, visit www.safemedicines.org<\/a>.<\/p>